Loading...

Length 
88 pages 

Date published 
August 2007 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Loading...

Country, Global license or Corporate subscription
Contact David Cunningham,
Global Report Sales
781-972-5472
cunningham@healthtech.com

Questions?
Contact Rose LaRaia
Customer Service
rlaraia@healthtech.com 
781-972-5444

Add to Del.icio.us Add to digg Add to Connotea Add to Facebook Add to LinkedIn Add to Twitter EMail Page Printer Friendly Book Mark

Survey Questions

Loading...

Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome

By Kevin Davies, PhD
 

SURVEY QUESTIONS

1. Please classify your organization.
 
2. What is your role in your organization? 
3. What is your chief application of DNA sequencing?
 
4. What organisms do you chiefly sequence?
 
5. Do you have experience with any next-generation sequencing technology?
 
6. Which next-generation sequencing platform do you feel holds the most promise?
 
7. Which applications will benefit most from next-generation sequencing?
 
8. What area of disease research will benefit most from next-generation sequencing?
 
9. What is the biggest technical concern about next-generation sequencing platforms?
 
10. What do you think of the reported cost of next-generation sequencing platforms (assume a range of $300,000–$600,000)?
 
11. What do you predict will be the cost of full human genome sequencing by 2010?
 
12. Do you think one platform will emerge dominant, as ABI did in Sanger sequencing?
 
13. Do you foresee a role for Sanger sequencing (capillary electrophoresis) after 2010?
 
14. Does society need Congress to pass GINA (Genetic Information Nondiscrimination Act)?